Sally has wealth of experience working with businesses at the cutting edge of research and technology and whose intellectual property is of prime importance.
Sally is one of our leading intellectual property (IP) partners. She provides a full range of intellectual property commercial advice and support to her clients, including licensing, partnering and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and ‘freedom to operate’ matters, and manages significant due diligence matters. As a transactional intellectual property lawyer, she provides advice in relation to the protection and exploitation of a full range of IP rights, both in stand alone transactions and as part of an acquisition, divestment or investment activity. Sally also works within the energy and utilities sector.
Before joining us in 2006, Sally was head of IP and Life Sciences at Eversheds, and prior to that she spent 11 years working in-house firstly as senior legal advisor at ICI/Zeneca and latterly as Legal Director of Novartis UK. This in-house experience gave her significant insight into the need to give pragmatic and commercial advice.
Sally speaks on a variety of IP and regulatory life sciences topics at conferences and contributes to many leading publications; she is also the editor of theThe Guide to EU Pharmaceutical Regulatory Law(published by Kluwer Law International), which is written entirely by the team at Bird & Bird with contributions from many offices. Sally is also leading the Bird & Bird Brexit Steering Committee; she gives regular talks and has published several articles on the implications of Brexit for the life sciences and medical devices industries.